Efficacy of bone resorption inhibitors (BRI) plus abiraterone acetate plus prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry

Francini, E; Montagnani, F; Vitale, Np; Alimohamed, Ns; Candilejo, Im; Rosellini, P; Gonzalez-Velez, M; Rubio, J; Zhang, L; Shaw, G; Crivelli, F; Petrioli, R; Bengala, C; Francini, G; Foncillas, Jg; Bryce, Ah; Sweeney, C; Harshman, Lc; Lee-Ying, R; Heng, Dyc

doi:10.1200/JCO.2019.37.15_suppl.e16508

https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.e16508

Efficacy of bone resorption inhibitors (BRI) plus abiraterone acetate plus prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry / Francini, E; Montagnani, F; Vitale, NP; Alimohamed, NS; Candilejo, IM; Rosellini, P; Gonzalez-Velez, M; Rubio, J; Zhang, L; Shaw, G; Crivelli, F; Petrioli, R; Bengala, C; Francini, G; Foncillas, JG; Bryce, AH; Sweeney, C; Harshman, LC; Lee-Ying, R; Heng, DYC. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - ELETTRONICO. - 37:(2019), pp. e16508-e16508. [10.1200/JCO.2019.37.15_suppl.e16508]